Kalshi Approved for Gold and Silver Perpetual Futures, Putting Pressure on Traditional Exchanges
nashnova research
Prediction-market platform Kalshi has won CFTC approval to list gold and silver perpetual futures on September 11 — the first non-crypto perpetual futures on a regulated U.S. venue, and a direct challenge to legacy exchanges.
What are perpetual futures, and why do they matter?
A perpetual future is a futures-style contract with no expiry date; a funding-rate mechanism keeps its price anchored to spot. Until now, perps traded almost exclusively on unregulated offshore crypto exchanges, with annual volume reaching $90 trillion.
This means → a massive market sat outside U.S. regulation for years. Kalshi is pulling it into a compliant framework.
Kalshi proved the model in May with crypto perps, which have since logged $44 billion in notional volume. Gold and silver are step two.
Why gold and silver?
Kalshi's commodity event contracts — covering metals and oil — hit $400 million in volume within seven months. Crypto event contracts took roughly 14 months to reach the same milestone.
In plain terms = demand for precious-metals contracts grew twice as fast as crypto — the market voted with its wallet.
Chief Risk Officer Udesh Jha put it simply: "Metals, especially gold and silver, have a story to tell because of inflation."
Why are legacy exchanges worried?
Since Kalshi's perps went live, share prices at both the Chicago Board Options Exchange (CBOE) and CME Group have declined.
CME has gone further, suing the CFTC and arguing the regulator followed improper procedures when approving perpetual futures.
This reflects a deeper fear: legacy exchanges are not worried about one or two new contracts — they are worried that the perpetual-futures format itself could erode their expiring-contract business model.
What comes next?
In August Kalshi filed to list perps tied to U.S. equities, industrial-metal copper, and foreign exchange — all awaiting CFTC review.
This means → if approved, perpetual futures move from niche alternative to a standardized tool spanning multiple asset classes.
CME's lawsuit is the key variable. If the court upholds the "improper procedure" claim, the approval pipeline could slow across the board.
市场有风险，内容仅供研究参考，不构成投资建议。